Efficacy of Bloodletting Therapy in Patients with Chronic Idiopathic Urticaria: A Randomized Control Trial
Table 1
| Eligibility criteria.
Eligibility criteria
Details
Diagnostic criteria
Spontaneous wheals and/or angioedema >6 weeks;
Average wheal duration <24 h;
Exclusion of physical urticaria and other chronic urticaria types.
Inclusion criteria
Age 18–70 years;
Wheals and pruritus present almost daily, UAS7 ≥ 28;
Regular subsequent visits.
Exclusion criteria
Usage of antihistamines within three days or corticosteroids, nonsteroidal anti-inflammatory drugs, and immunosuppressive drugs within one month before inclusion;
Course of disease >2 years;
Autoimmune urticaria;
Autoimmune diseases;
Allergic to ebastine;
Pregnant or breast-feeding women;
Thrombocytopenia and coagulation disturbance;
Abnormal liver and kidney function;
Trauma/infection;
Accompanied by fever, dizziness, headache or vomiting;
Cardiovascular and cerebrovascular disease, diabetes, kidney disease, abnormal bone metabolism, and acute attack of asthma;
Mental disorder;
Ulcer, infection, or scar on treated skin;
Mistakenly enrolled;
Severe systemic symptoms or other serious diseases found during treatment;
